Biomarker
Omega-3 Index
Red blood cell omega-3 index
The percentage of EPA and DHA in red blood cell membranes, a stable biomarker of long-term omega-3 status linked to cardiovascular risk.
Summary Does the omega-3 index show whether I get enough EPA and DHA? Show / hide ↓
The omega-3 index measures how much EPA and DHA, two marine omega-3 fats, are found in your red blood cells. Because these cells last about 120 days, the result reflects your usual intake over weeks or months rather than just your last meal. Studies link higher results with lower cardiovascular risk, but the suggested target of 8–12% and the higher-risk level below about 4% are not firmly agreed on. Fish and supplements reliably raise the index, but studies of health benefits have had mixed results: high-dose purified EPA reduced heart problems in one high-risk group, while several lower-dose mixed products did not. The test is fairly stable but requires a specialized laboratory and is not routinely included in standard blood panels.
What this means for you: The omega-3 index is a useful measure of long-term EPA and DHA status, but it does not guarantee better health. Raising it may help some high-risk people, while the benefit depends on the product, amount, and starting risk.
conflicting evidenceThe omega-3 index is the percentage of total red blood cell (erythrocyte) membrane fatty acids accounted for by the marine omega-3 fatty acids EPA and DHA. Developed and validated primarily by Harris and colleagues, it was proposed as a more reliable indicator of long-term omega-3 status than a single plasma measurement, because red blood cell turnover is slow (roughly 120 days) and the membrane composition reflects habitual intake over weeks to months rather than the last meal.
Why it matters: the omega-3 index has been associated, in observational and cohort analyses, with cardiovascular outcomes, including sudden cardiac death, and a range of proposed optimal thresholds has been published. A commonly cited working target is 8-12% as a lower-risk range, with values below roughly 4% considered higher risk, though cutoffs are population- and outcome-dependent and remain debated.
The interventional evidence for raising the index is clear: EPA and DHA intake from fish or fish-oil supplements reliably increases the omega-3 index in a dose-dependent manner. Whether raising the index translates to hard clinical benefit is more contested. The REDUCE-IT trial of high-dose icosapent ethyl (a purified EPA ester) in high-risk patients on statins showed a significant reduction in cardiovascular events, supporting a benefit of EPA in a specific high-risk population; other large omega-3 trials using lower doses or DHA-containing mixes have been neutral, so the benefit appears dose-, formulation-, and population-dependent rather than universal.
Measurement is by specialized gas chromatography of red blood cell membranes, available through reference laboratories; it is not part of routine clinical panels in most countries. The index is more reproducible and stable than plasma omega-3 but is still subject to assay calibration differences between labs.
Plain takeaway: the omega-3 index is a stable, intake-responsive biomarker of long-term EPA/DHA status with plausible and partly trialed cardiovascular relevance; raising it through omega-3 intake is straightforward, but the hard clinical benefit depends on dose, formulation, and baseline risk.
Products with this: Omega-3 (EPA/DHA)
Further reading
Curated external sources for a deeper dive. External links open in a new tab.
- Omega-3 fatty acids and cardiovascular disease - REDUCE-IT (icosapent ethyl) PubMed (REDUCE-IT, NEJM)
- The Omega-3 Index: a new risk factor for sudden cardiac death? Harris et al. PubMed (Harris et al.)
Follow Omega-3 Index through the chain: the mechanism that moves it, the molecule that targets it, the products that dose it, and the trials that tested it.
See Omega-3 Index on the Longevity Map →